Cat. No. 1620
Alternative Names: PGE1, Prostaglandin E1
Chemical Name: (11α,13E,15S)-11,15-Dihydroxy-9-oxo-
Biological ActivityProstaglandin with some selectivity for EP3 and EP4 receptors (Ki values are 1.1, 2.1, 36, 10 and 33 nM for mouse EP3, EP4, EP1, EP2 and IP receptors respectively). Inhibits platelet aggregation and is a vasodilator in vivo.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
Kiriyama et al (1997) Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br.J.Pharmacol. 122 217. PMID: 9313928.
Kirtland (1988) Prostaglandin E1: a review. Prostaglandins Leukot.Essent.Fatty Acids 32 165. PMID: 2901111.
Whittle et al (1985) Specificity between the anti-aggregatory actions of prostacyclin, prostaglandin E1 and D2 on platelets. Adv.Exp.Med.Biol. 192 109. PMID: 2871707.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Alprostadil from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Alprostadil, supplier, Prostaglandin, Vasodilator, anti-platelet, agent, vivo, Receptors, TP, EP1, EP2, EP3, EP4, Prostanoid, prostaglandins, prostacyclins, eicosanoids, PGE1, Tocris Bioscience, Prostanoid Receptor products
Find multiple products by catalog number
New Products in this Area
Highly potent P2Y12 antagonistFTY 720
Potent S1P receptor agonist; also immunosuppresentCinacalcet hydrochloride
Calcium-sensing receptor (CaSR) allosteric agonist; also CYP2D2 inhibitor and Ca2+ channel blocker; orally bioavailableAMG 837 hemicalcium salt
Potent free fatty acid receptor 1 (FFA1/GPR40) partial agonistUMB 68
GHB receptor ligandAZD 1283
High affinity P2Y12 antagonistEx 26
Potent and selective S1P1 receptor antagonistZQ 16
Selective GPR84 agonistIHR-Cy3
Potent fluorescent Smo antagonistRo 6842262
Potent LPA1 antagonistAMG 853
Potent dual CRTH2 and prostaglandin D2 (PGD2) receptor antagonistAM 4668
Potent FFA1 (GPR40) agonistCATPB
FFA2 antagonist/inverse agonist
April 22 - 26, 2017
Chicago, IL, USA